Cybin announced that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine, or DMT, has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1 trial was acquired from Entheon Biomedical Corp. in July 2022.
Published first on TheFly
